Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone in elderly newly diagnosed multiple myeloma
2020-004972-17Phase 2Active
- Sponsor
- AGMT
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by AGMT. Primary endpoint: MRD negativity after end of induction. Started Apr 2021; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-004972-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004972-17.